MacroGenics Inc. [NASDAQ: MGNX] traded at a high on 06/11/20, posting a 0.10 gain after which it closed the day’ session at $19.82. The results of the trading session contributed to over 1100281 shares changing hands. Over the past one week, the price volatility of MacroGenics Inc. stands at 8.40% while the volatility over the past one month is 9.78%.
The market cap for MGNX stock reached $998.73 million, with 49.01 million shares outstanding and 45.55 million shares in the current float. Compared to the average trading volume of 3.13M shares, MGNX reached a trading volume of 1100281 in the most recent trading day, which is why market watchdogs consider the stock to be active.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
What do top market gurus say about MacroGenics Inc. [MGNX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MGNX shares is $28.64 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MGNX stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for MacroGenics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on June 01, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $22 to $40. The new note on the price target was released on May 26, 2020, representing the official price target for MacroGenics Inc. stock. Previously, the target price had yet another raise to $8, while Barclays analysts kept a Underweight rating on MGNX stock.
The Average True Range (ATR) for MacroGenics Inc. is set at 2.76, with the Price to Sales ratio for MGNX stock in the period of the last 12 months amounting to 14.64. The Price to Book ratio for the last quarter was 5.10, with the Price to Cash per share for the same quarter was set at 3.39.
How has MGNX stock performed recently?
MacroGenics Inc. [MGNX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.22. With this latest performance, MGNX shares dropped by -27.00% in over the last four-week period, additionally plugging by 112.43% over the last 6 months – not to mention a rise of 32.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MGNX stock in for the last two-week period is set at 50.74, with the RSI for the last a single of trading hit 42.77, and the three-weeks RSI is set at 54.20 for MacroGenics Inc. [MGNX]. The present Moving Average for the last 50 days of trading for this stock 15.02, while it was recorded at 19.93 for the last single week of trading, and 11.35 for the last 200 days.
MacroGenics Inc. [MGNX]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and MacroGenics Inc. [MGNX] shares currently have an operating margin of -276.04. MacroGenics Inc.’s Net Margin is presently recorded at -236.51.
Return on Total Capital for MGNX is now -70.30, given the latest momentum, and Return on Invested Capital for the company is -60.60. Return on Equity for this stock declined to -64.12, with Return on Assets sitting at -47.10. When it comes to the capital structure of this company, MacroGenics Inc. [MGNX] has a Total Debt to Total Equity ratio set at 13.26. Additionally, MGNX Total Debt to Total Capital is recorded at 11.70, with Total Debt to Total Assets ending up at 9.78. Long-Term Debt to Equity for the company is recorded at 11.95, with the Long-Term Debt to Total Capital now at 10.55.
Reflecting on the efficiency of the workforce at the company, MacroGenics Inc. [MGNX] managed to generate an average of -$395,341 per employee. Receivables Turnover for the company is 3.03 with a Total Asset Turnover recorded at a value of 0.20.MacroGenics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 4.90 and a Current Ratio set at 4.90.
Earnings analysis for MacroGenics Inc. [MGNX]
With the latest financial reports released by the company, MacroGenics Inc. posted -0.65/share EPS, while the average EPS was predicted by analysts to be reported at -0.99/share.When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 34.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MGNX.
Insider trade positions for MacroGenics Inc. [MGNX]
There are presently around $888 million, or 92.50% of MGNX stock, in the hands of institutional investors. The top three institutional holders of MGNX stocks are: BELLEVUE GROUP AG with ownership of 6,119,150, which is approximately 4.185% of the company’s market cap and around 2.30% of the total institutional ownership; BLACKROCK INC., holding 4,775,157 shares of the stock with an approximate value of $94.55 million in MGNX stocks shares; and INVESCO LTD., currently with $88.7 million in MGNX stock with ownership of nearly -0.428% of the company’s market capitalization.
Positions in MacroGenics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 54 institutional holders increased their position in MacroGenics Inc. [NASDAQ:MGNX] by around 3,534,913 shares. Additionally, 67 investors decreased positions by around 4,197,915 shares, while 23 investors held positions by with 37,120,595 shares. The mentioned changes placed institutional holdings at 44,853,423 shares, according to the latest SEC report filing. MGNX stock had 20 new institutional investments in for a total of 852,518 shares, while 21 institutional investors sold positions of 1,937,797 shares during the same period.